FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
The Pharma Letter7d
Imfinzi first immunotherapy to win LS-SCLC nod
AstraZeneca’s Imfinzi (durvalumab) has been approved in the USA for the treatment of adults with limited-stage small cell ...
Cancer Therapy Advisor6d
Imfinzi Approved as Consolidation in LS-SCLC
The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.
AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC ...
Yahoo Finance7d
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS-SCLC) in the adult population.
pharmaphorum7d
FDA clears AZ's Imfinzi for aggressive lung cancer
Imfinzi is already approved for extensive-stage SCLC based on the results of the CASPIAN trial, as well as for locally ...
WebMD3d
FDA Approves Drug for Aggressive Small-Cell Lung Cancer
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...
Medscape6d
FDA Approves Durvalumab for Limited-Stage SCLC
Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
FiercePharma7d
AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell lung cancer
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
Zacks.com on MSN7d
AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC ...